These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36483361)

  • 21. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
    Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
    Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
    Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and outcomes of patients receiving outpatient parenteral antibiotic therapy in a Belgian setting: a single-center pilot study.
    Briquet C; Cornu O; Servais V; Blasson C; Vandeleene B; Yildiz H; Stainier A; Yombi JC
    Acta Clin Belg; 2020 Aug; 75(4):275-283. PubMed ID: 31023169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
    Petrakis V; Panagopoulos P; Papanas N
    Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller : Proposal for novel treatment indications.
    Mischlinger J; Lagler H; Harrison N; Ramharter M
    Wien Klin Wochenschr; 2017 Sep; 129(17-18):642-645. PubMed ID: 28776100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
    Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
    J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
    Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
    Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
    Rappo U; Puttagunta S; Shevchenko V; Shevchenko A; Jandourek A; Gonzalez PL; Suen A; Mas Casullo V; Melnick D; Miceli R; Kovacevic M; De Bock G; Dunne MW
    Open Forum Infect Dis; 2019 Jan; 6(1):ofy331. PubMed ID: 30648126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience in the use of dalbavancin in diabetic foot infection.
    Navarro-Jiménez G; Fuentes-Santos C; Moreno-Núñez L; Alfayate-García J; Campelo-Gutierrez C; Sanz-Márquez S; Pérez-Fernández E; Velasco-Arribas M; Hervás-Gómez R; Martín-Segarra O; Losa-García JE
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Jan; ():. PubMed ID: 33451810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
    Ruiz-Sancho A; Núñez-Núñez M; Castelo-Corral L; Martínez-Marcos FJ; Lois-Martínez N; Abdul-Aziz MH; Vinuesa-García D
    Front Pharmacol; 2023; 14():1185602. PubMed ID: 37448966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience in the use of dalbavancin in diabetic foot infection.
    Navarro-Jiménez G; Fuentes-Santos C; Moreno-Núñez L; Alfayate-García J; Campelo-Gutierrez C; Sanz-Márquez S; Pérez-Fernández E; Velasco-Arribas M; Hervás-Gómez R; Martín-Segarra O; Losa-García JE
    Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):296-301. PubMed ID: 35490091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.
    Esposito S; Pagliano P; De Simone G; Guarino A; Pan A; Brambilla P; Mastroianni C; Lichtner M; Brugnaro P; Carretta A; Santantonio T; Brindicci G; Carrega G; Montagnani F; Lapadula G; Spolti A; Luzzati R; Schiaroli E; Scaglione V; Pallotto C; Tacconi D; Quintieri F; Trecarichi E;
    Infection; 2024 Feb; ():. PubMed ID: 38324144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.
    Wilke M; Worf K; Preisendörfer B; Heinlein W; Kast T; Bodmann KF
    GMS Infect Dis; 2019; 7():Doc03. PubMed ID: 31728264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
    Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
    J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.